Japanese pharmaceutical companies have lined up to develop a myriad of solutions to treat COVID-19 infections. One such company here…...
Please subscribe to read the full story.
Nippon Shinyaku
Nippon Shinyaku Targets 2019 Approval for New Muscular Dystrophy Treatment
Nippon Shinyaku Co. Ltd. (TYO:4516) has completed Phase 2 clinical trials in the U.S. for NS-065 as of this February…....
Please subscribe to read the full story.
